Abstracts and notes on CML presentations from ASH 2014 San Francisco
Professor Steve O’Brien, Newcastle University, UK
Professor Steve O’Brien, Newcastle University, UK
Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:
Clinical papers
Webstreams of the presentations and discussions from the iCMLf Forum 2022 that took place on December 9th 2022 in News Orleans (USA), are now available to view. At this forum, our speakers and panellists of renowned experts in the field took a look at future directions of CML. What are the next big challenges in CML? What are the most promising new approaches? What research questions need to be answered to help us to move closer to a cure for CML?
Topics include:
Please click on the link below access a selection of interesting articles on CML from peer-reviewed journals, including:
Hear about current practices for third-line management of CML and get first-hand expert knowledge from:
Professor Andreas Hochhaus
Head of the Department of Hematology and Medical Oncology,
Jena University Hospital, Germany
Date: August 24th 2022 at 2 pm Central European Summer Time (CEST)
How can I dial into the webinar?
Join this meeting from your computer, tablet or smartphone via the link:
https://us02web.zoom.us/j/87340646441
CML Highlights of EHA 2022 – Biological and clinical overview
Join our two experts as they discuss key aspects of the CML presentations:
Clinical overview: Professor Timothy Hughes,
Precision Medicine Theme Leader at SAHMRI, Beat Cancer Professor at the University of Adelaide and Consultant Haematologist, Royal Adelaide Hospital (Australia)
Biological overview: Professor Dominik Wolf, Head, Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck (Austria)
International CML foundation's Newsletter June 2022
GOLDMAN PRIZE- Professor Andreas Hochhaus (Germany)
ROWLEY PRIZE- Professor Oliver Hantschel (Germany)
Jane Apperley- 40-years in medicine
Ravi Bhatia, MD- The leukaemia stem cell in its niche- the quest for cure
'Among challenges of TFR, it is also included the better identification of patients who have a high probability of relapsing compared with those who experience a successful TFR. Some of the most promising data involve the field of immunology, especially T-cell cytotoxicity and NK cell effects. In several studies, NK cell numbers or functional subsets of NK cells were shown to be higher in patients who maintain TFR than in those who lose molecular response during TKI discontinuation.'
This review will present the current studies that are helping to increase our understanding of the biological factors (clinical and non-clinical, cellular, and molecular) that may determine TKI discontinuation success
https://link.springer.com/article/10.1007/s11912-022-01228-w
CML Advocates Network have provided a helpful summary of 63rd ASH meeting: CML abstracts and presentations
https://www.cmladvocates.net/download/scientific-conferences/ash-2021/1152-ash-2021-cml-report/file